Cargando…

Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report

Peripheral edema is observed as an adverse effect of the usage of antipsychotics in the literature. This case report describes a 36-year-old female patient with the diagnosis of paranoid schizophrenia who presented with pretibial edema following initiation of long-acting injectable paliperidone palm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cicek, Erdinc, Cicek, Ismet Esra, Uguz, Faruk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean College of Neuropsychopharmacology 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426490/ https://www.ncbi.nlm.nih.gov/pubmed/28449568 http://dx.doi.org/10.9758/cpn.2017.15.2.184

Ejemplares similares

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
por: de Azevedo Avelar, Rita, et al.
Publicado: (2020)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Patel, R., et al.
Publicado: (2018)

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
por: Mahlich, Jörg, et al.
Publicado: (2015)

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
por: Mason, Katy, et al.
Publicado: (2021)

Bilateral pretibial edema associated with risperidone: A case report
por: Yildiz, B., et al.
Publicado: (2023)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
por: Evernden, Christopher, et al.
Publicado: (2021)

Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Desai, Mitesh, et al.
Publicado: (2018)

Clinical Study of Paliperidone Palmitate Long-Acting Injection Combined With Electroacupuncture in the Treatment of Methamphetamine Addicts
por: Chen, Yu, et al.
Publicado: (2021)

Etoricoxib-induced pretibial erythema and edema
por: Kumar, Pramod
Publicado: (2015)

Long-acting injectable paliperidone palmitate induced severe cutaneous allergic reaction in a patient with first episode delusional disorder tolerating oral paliperidone regimen: a case report
por: Borojevic, Natasa, et al.
Publicado: (2022)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?
por: Ravenstijn, Paulien, et al.
Publicado: (2016)

PM411. Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
por: Brown, Brianne, et al.
Publicado: (2016)

Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
por: Brown, Brianne, et al.
Publicado: (2019)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such, Pedro, et al.
Publicado: (2021)

Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
por: Oh, Jihoon, et al.
Publicado: (2023)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada, Ryohei, et al.
Publicado: (2018)

Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
por: Debaveye, Sam, et al.
Publicado: (2019)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
por: Zhao, Mingjun, et al.
Publicado: (2023)

Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study
por: Kane, John M., et al.
Publicado: (2019)

Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
por: Markowitz, Michael, et al.
Publicado: (2013)

A Case of Ileus in a Patient with Schizophrenia Under Paliperidone Palmitate Treatment
por: Can, Serdar Süleyman, et al.
Publicado: (2016)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

S203. EFFECT OF LONG-ACTING INJECTIONS OF PALIPERIDONE PALMITATE ON CLINICAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH SCHIZOPHRENIA BASED ON ILLNESS DURATION
por: Kim, Seoyoung, et al.
Publicado: (2020)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

Long-acting paliperidone palmitate – interim results of an observational study of its effect on hospitalization
por: Taylor, David, et al.
Publicado: (2014)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
por: Kim, Shiyun, et al.
Publicado: (2012)

Paliperidone Palmitate-induced Urinary Incontinence: A Case Report
por: Karslıoǧlu, Ersin Hatice, et al.
Publicado: (2016)

Paliperidone palmitate-induced facial angioedema: A case report
por: Srifuengfung, Maytinee, et al.
Publicado: (2020)

Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
por: Alphs, Larry, et al.
Publicado: (2011)

F228. EFFECTIVENESS OF PALIPERIDONE PALMITATE VS OTHER LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTICS – AN ELECTRONIC CASE REGISTER STUDY
por: Patel, Rashmi, et al.
Publicado: (2018)

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
por: García-Carmona, Juan Antonio, et al.
Publicado: (2023)

Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs
por: Di Lorenzo, Rosaria, et al.
Publicado: (2022)

Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations
por: Fife, Daniel, et al.
Publicado: (2022)

Long-acting Paliperidone Palmitate treatment in an Ekbom’s Syndrome secondary to Lewy Body Dementia: A case report
por: Orsolini, L., et al.
Publicado: (2022)

Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review
por: González-Rodríguez, Alexandre, et al.
Publicado: (2015)

Increased Neutrophil-lymphocyte and Platelet-lymphocyte Ratios in Male Heroin Addicts: A Prospective Controlled Study
por: Cıcek, Erdinc, et al.
Publicado: (2018)

Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France
por: Limosin, Frédéric, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6hl4asvnurgp0ch55hirpdnsbr